Mintezol Side Effects
Generic Name: thiabendazole
Note: This document contains side effect information about thiabendazole. Some of the dosage forms listed on this page may not apply to the brand name Mintezol.
Applies to thiabendazole: compounding powder, oral suspension, oral tablet chewable
Gastrointestinal side effects have commonly included nausea, vomiting, anorexia, and abdominal pain. These side effects generally only last 1 to 2 days and do not require drug discontinuation. Epigastric distress and abdominal pain have also been reported.[Ref]
Nervous system side effects have included drowsiness, dizziness, giddiness, headache, paresthesias, weariness, numbness, hyperirritability, convulsions, collapse, confusion, depression, floating sensation, weakness, and lack of coordination.[Ref]
Erythema multiforme (including Stevens-Johnson syndrome) and toxic epidermal necrolysis generally do not occur for several weeks after thiabendazole (the active ingredient contained in Mintezol) is discontinued. The reaction generally starts with a skin eruption which quickly progresses. Two reported cases had complete recovery after several weeks of therapy.[Ref]
Hypersensitivity adverse effects have included pruritic rash reactions, fever, facial flush, chills, conjunctival injection, angioedema, anaphylaxis, skin rashes (including perianal), erythema multiforme (including Stevens-Johnson syndrome), toxic epidermal necrolysis, and lymphadenopathy.[Ref]
Sicca complex has been frequently noted with the hepatic changes associated with thiabendazole (the active ingredient contained in Mintezol) This clinical picture includes keratoconjunctivitis sicca and xerostomia. This also appears to be reversible in most cases without medical intervention.[Ref]
Hepatic side effects reported have included liver damage. It may manifest as jaundice, cholestasis, sicca syndrome, malaise, light-colored stools, and gastrointestinal upset. These symptoms generally do not occur for several weeks following thiabendazole therapy completion. Therapy usually consists of only supportive measures. In most cases the hepatic damage is reversible, although at least one patient has died as a result of hepatic damage. Sicca complex has also been reported.[Ref]
Ocular side effects have included abnormal sensation in eyes, xanthopsia, blurred vision, and transient disturbances in vision.
Cardiovascular side effects have included hypotension.
Metabolic side effects have included hyperglycemia.
Hematologic side effects have included transient leukopenia.
Psychiatric side effects have included psychic alterations.
1. Grove DI "Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectiveness." Trans R Soc Trop Med Hyg 76 (1982): 114-8
2. Gann PH, Neva FA, Gam AA "A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis." J Infect Dis 169 (1994): 1076-9
3. Nauenberg W, Edelman MH, Spingarn CL "Observations on the treatment of strongyloidiasis with thiabendazole in New York City." Mt Sinai J Med 37 (1970): 607-11
4. Tanowitz HB, Wittner M "Probable thiabendazole allergy after repeated administration." J Trop Med Hyg 73 (1970): 141-2
5. Fink AI, MacKay CJ, Cutler SS "Sicca complex and cholangiostatic jaundice in two members of a family probably caused by thiabendazole." Ophthalmology 86 (1979): 1892-6
6. Rex D, Lumeng L, Eble J, Rex L "Intrahepatic cholestasis and sicca complex after thiabendazole: report of a case and review of the literature." Gastroenterology 85 (1983): 718-21
7. Manivel JC, Bloomer JR, Snover DC "Progressive bile duct injury after thiabendazole administration." Gastroenterology 93 (1987): 245-9
8. Jalota R, Freston JW "Severe intrahepatic cholestasis due to thiabendazole." Am J Trop Med Hyg 23 (1974): 676-8
9. Roy MA, Nugent FW, Aretz HT "Micronodular cirrhosis after thiabendazole." Dig Dis Sci 34 (1989): 938-41
10. Bion E, Pariente EA, Maitre F "Severe cholestasis and sicca syndrome after thiabendazole." J Hepatol 23 (1995): 762-3
Some side effects may not be reported. You may report them to the FDA.